Latest News and Press Releases

SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...

New interim survival data from the ongoing RESCUE-ALS long-term open label extension (OLE) study demonstrate that early treatment (original randomization to active CNM-Au8) decreased risk of mortality...

$3 million 60-month loan to support capital equipment purchases in new 75,000-square-foot facility in Elkton, Maryland, for manufacture of Clene’s lead drug candidate, CNM-Au8®, for treatment of ALS ...

SALT LAKE CITY, May 16, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...

Cash, cash equivalents, restricted cash and marketable securities of $36.6 million as of March 31, 2022Additional data from RESCUE-ALS presented at 2022 AAN Annual Meeting and MDA Clinical &...

SALT LAKE CITY, April 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...

Analyses of long-term open-label extension of RESCUE-ALS trial indicate improved survival compared to predictions derived from validated ENCALS risk modelInterim results demonstrate approximately 70%...

Cash and restricted cash of $50.3 million as of December 31, 2021Visionary-MS Phase 2 Trial unblinded results expected 2H 2022Healey ALS Platform Trial top-line data expected 2H 2022COVID-19 Phase 2...

SALT LAKE CITY, March 03, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...

VISIONARY-MS Phase 2 blinded interim data suggest clinically relevant improvements in the modified MS Functional Composite for the study population through 48 weeks of treatment REPAIR-MS Phase 2...